Veysel Haksoyler1, Ali A Besen2, Tolga Koseci3, Polat Olgun4, Ertugrul Bayram5, Erkan Topkan6. 1. Department of Medical Oncology, Medline Hospital, Adana, Turkey. 2. Department of Medical Oncology, Baskent University Medical Faculty, Adana, Turkey. 3. Department of Medical Oncology, City Hospital, Adana, Turkey. 4. Department of Medical Oncology, Near East University, Cyprus, Turkey. 5. Department of Medical Oncology, Cukurova University, Adana, Turkey. 6. Department of Radiation Oncology, Baskent University Medical Faculty, Adana, Turkey.
Abstract
Aim: We intended to survey the prognostic utility of pretreatment neutrophil-to-lymphocyte ratio (NLR) as a novel prognostic index in recurrent glioblastoma multiforme (R-GBMs) treated with bevacizumab plus irinotecan (BEVIRI). Patients & methods: The present retrospective investigation incorporated the R-GBMs patients who underwent BEVIRI. The pre-BEVIRI NLR was calculated for each patient by utilizing the complete blood count tests obtained on the first day of BEVIRI. Results: The data of a total of 103 patients were analyzed. The ideal cutoff was identified at 3.04 (area under the curve: 60%; sensitivity: 60.3%; specificity 60%) for the pre-BEVIRI NLR. Low-NLR group had significantly longer overall survival times than the high-NLR group (15.8 vs 9.3 months; p = 0.015). Conclusion: NLR might be utilized as a novel biomarker in the prognostic stratification of the R-GBMs treated with BEVIRI.
Aim: We intended to survey the prognostic utility of pretreatment neutrophil-to-lymphocyte ratio (NLR) as a novel prognostic index in recurrent glioblastoma multiforme (R-GBMs) treated with bevacizumab plus irinotecan (BEVIRI). Patients & methods: The present retrospective investigation incorporated the R-GBMs patients who underwent BEVIRI. The pre-BEVIRI NLR was calculated for each patient by utilizing the complete blood count tests obtained on the first day of BEVIRI. Results: The data of a total of 103 patients were analyzed. The ideal cutoff was identified at 3.04 (area under the curve: 60%; sensitivity: 60.3%; specificity 60%) for the pre-BEVIRI NLR. Low-NLR group had significantly longer overall survival times than the high-NLR group (15.8 vs 9.3 months; p = 0.015). Conclusion: NLR might be utilized as a novel biomarker in the prognostic stratification of the R-GBMs treated with BEVIRI.
Authors: George S Stoyanov; Emran Lyutfi; Reneta Georgieva; Deyan L Dzhenkov; Lilyana Petkova; Borislav D Ivanov; Ara Kaprelyan; Peter Ghenev Journal: Cureus Date: 2022-06-09